Skip to main content
SpringerLink
Log in

Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers

  • Chapter
  • First Online:
Cardiac Drug Therapy

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 3892 Accesses

Abstract

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) play a pivotal role in the management of heart failure (HF) and hypertension. These agents are mildly cardioprotective and increase survival somewhat in patients with:

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • ACCOMPLISH: Jamerson K, Weber MA, Bakris GL et al For the ACCOMPLISH trial investigators (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl JMed 359:2417–2428.

    Google Scholar 

  • Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators, et al. The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 1995;332:80.

    Article  CAS  PubMed  Google Scholar 

  • ATLAS Study Group, Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril on morbidity and mortality in chronic heart failure. Circulation. 1999;100:2312.

    Article  CAS  PubMed  Google Scholar 

  • Burnier M. Angiotensin II, type 1 receptor blockers. Circulation. 2001;103:904.

    Article  CAS  PubMed  Google Scholar 

  • Cameron DI. Near fatal angioedema associated with captopril. Can J Cardiol. 1990;6:265.

    CAS  PubMed  Google Scholar 

  • Caskey FJ, Thacker EJ, Johnston PA, et al. Failure of losartan to control blood pressure in scleroderma renal crisis. Lancet. 1997;349:620.

    Article  CAS  PubMed  Google Scholar 

  • Cicoira M, Zanolla L, Rossi A. Failure of aldosterone suppression despite angiotensin converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol. 2001;37:1808.

    Article  CAS  PubMed  Google Scholar 

  • Cleland JGF, Henderson E, McLenachan J, et al. Effect of captopril, an angiotensin converting enzyme inhibitor, in patients with angina pectoris and heart failure. J Am Coll Cardiol. 1991;17:733.

    Article  CAS  PubMed  Google Scholar 

  • Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303.

    Article  CAS  PubMed  Google Scholar 

  • CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429.

    Article  Google Scholar 

  • Davis JO, Freeman RH. Mechanisms regulating renin release. Physiol Rev. 1976;56:1.

    CAS  PubMed  Google Scholar 

  • DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551–62.

    Article  Google Scholar 

  • ELITE II, Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality on patients with symptomatic heart failure: randomized trial. The Losartan Heart Failure Study. Lancet. 2000;255:1582.

    Article  Google Scholar 

  • Ferner RE, Simpson JM, Rawlings MD. Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme. BMJ. 1987;294:1119.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Ganong WF. The brain renin-angiotensin system. Annu Rev Physiol. 1984;46:17.

    Article  CAS  PubMed  Google Scholar 

  • Giannoccaro PJ, Wallace GJ, Higginson L, et al. Fatal angioedema associated with enalapril. Can J Cardiol. 1989;5:335.

    CAS  PubMed  Google Scholar 

  • Giles TD, Weber MA, Basile J, for the NAC-MD-01 Study Investigators, et al. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Lancet. 2014;383:1889–98.

    Article  CAS  PubMed  Google Scholar 

  • HOPE Investigators, Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med. 2000;342:145.

    Article  CAS  PubMed  Google Scholar 

  • Hricik DE, Browning PJ, Kopelman R, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med. 1983;308:373.

    Article  CAS  PubMed  Google Scholar 

  • Ingelfinger JR. Editorial. Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes. N Engl J Med. 2011;364:970–1.

    Article  CAS  PubMed  Google Scholar 

  • Jett GK. Captopril-induced angioedema. Ann Emerg Med. 1984;13:489.

    Article  CAS  PubMed  Google Scholar 

  • Kochar MS, Bolek G, Kalbfleish JF, et al. A 52 week comparison of lisinopril, hydrochlorothiazide and their combination in hypertension. J Clin Pharmacol. 1987;27:373.

    Article  CAS  PubMed  Google Scholar 

  • Leary WP, Reyes AJ. Angiotensin I converting enzyme inhibitors and the renal excretion of urate. Cardiovasc Drugs Ther. 1987;1:29.

    Article  CAS  PubMed  Google Scholar 

  • Lewis EJ, Hunsicker LG, Bain RP, for the Collaborative Study Group, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–62.

    Article  CAS  PubMed  Google Scholar 

  • Lewis EJ, Hunsicker LG, Clarke WR, for the Collaborative Study Group, et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851.

    Article  CAS  PubMed  Google Scholar 

  • Lunde H, Hedner T, Samuelsson O, et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ. 1994;308:18.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • McMurray JV, Swedberg K (2010) HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure–lessons learnt from a decade of trials. Eur J Heart Fail 12(2):99–103.

    Google Scholar 

  • Munzel T, Keaney JF. Are ACE inhibitors a “magic bullet” against oxidative stress? Circulation. 2001;104:1571.

    Article  CAS  PubMed  Google Scholar 

  • ONTARGET: The ONTARGET Investigators (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559.

    Google Scholar 

  • Parving H-H, Lehnert H, Brochner-Mortensen J, for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870.

    Article  CAS  PubMed  Google Scholar 

  • Pfeffer MA, Braunwald E. Ventricular remodelling after myocardial infarction: experimental observations and clinical implications. Circulation. 1990;81:1161.

    Article  CAS  PubMed  Google Scholar 

  • PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood pressure lowering regimen among, individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033.

    Article  Google Scholar 

  • PRoFESS, Yusuf S, Diener H-C, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Eng J Med. 2008a; 359(12):1225–37.

    Google Scholar 

  • Reid IA. The renin-angiotensin system and body function. Arch Intern Med. 1985;145:1475.

    Article  CAS  PubMed  Google Scholar 

  • RENAAL Study Investigators, Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861.

    Article  CAS  PubMed  Google Scholar 

  • ROADMAP Trial Investigators, Haller H, Ito S, Izzo Jr JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907–17.

    Article  CAS  PubMed  Google Scholar 

  • The ONTARGET Investigators (2008). Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events Randomized,– April 10, 2008. N Engl J Med 2008; 358:1547-1559. http://www.nejm.org/doi/full/10.1056/NEJMoa0801317

  • SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293.

    Article  Google Scholar 

  • Topol EJ, Thomas A, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med. 1985;312:277.

    Article  CAS  PubMed  Google Scholar 

  • Torretti J. Sympathetic control of renin release. Annu Rev Pharmacol Toxicol. 1982;22:167.

    Article  CAS  PubMed  Google Scholar 

  • Val-HeFT, Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–75.

    Article  CAS  PubMed  Google Scholar 

  • Weber KT. Aldosterone and spironolactone in heart failure. N Engl J Med. 1999;341:753.

    Article  CAS  PubMed  Google Scholar 

  • Weinsaft JW (2000) Effect of ramipril on cardiovascular events in highrisk patients. N Engl J Med 343:64–66.

    Google Scholar 

  • Yusuf S, Teo K, Anderson C et al for the TRANSCEND Investigators (2008b) Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensinconverting enzyme inhibitors: a randomised controlled trial. Lancet 372:1174–1183. TRANSCEND.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Ottawa The Ottawa Hospital, Ottawa, ON, Canada

    M. Gabriel Khan MD, FRCPC, FRCP (London), FACC

Authors
  1. M. Gabriel Khan MD, FRCPC, FRCP (London), FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Khan, M.G. (2015). Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers. In: Cardiac Drug Therapy. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-962-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-962-4_3

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61779-961-7

  • Online ISBN: 978-1-61779-962-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation